Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancer

Abstract

Prior studies have suggested that the RAS-ERK-FOXM1 pathway contributes to adaptive cellular responses and chemotherapy resistance. We investigate a role of MEK inhibitors to block adaptive responses in ovarian cancers initiated by the RAS-ERK-FOXM1 pathway to improve platinum chemotherapy sensitivity.